Tafasitamab – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 25 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Medical guide Drugs (A - Z) Feb 8, 2026 43 reads
Related reading

Tafasitamab - Uses, Dosage, Side Effects, Interactions
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.[rx] It is produced using recombinant DNA technology in Chinese hamster ovary cells and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.[rx] It is produced using recombinant DNA technology in Chinese hamster ovary cells and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19 antibodies.[rx],[rx] The CD19 surface protein is highly expressed on the surface of B-cells, where it...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.[rx] It is produced using recombinant DNA technology in Chinese hamster ovary cells and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19 antibodies.[rx],[rx]

The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.[rx] Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes,[rx], as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[rx], has made it a desirable target in the treatment these B-cell malignancies. Tafasatimab is designed to bind to and block the activity of the CD19 surface antigen, which ultimately results in the lysis of B-cells (both healthy and malignant).[rx]

Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from the FDA,[rx] tafasatimab-cxix (Monjuvi®) received accelerated approval on July 31st, 2020, for the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants.[rx] It must be used in combination with lenalidomide, as this combination results in greater efficacy as compared to either agent alone.[rx]

Mechanism of action

The CD19 surface antigen is a protein expressed on the surface of pre-B and mature B-lymphocytes[rx] that appears to play a role in enhancing B-cell receptor signaling and is considered integral to their survival.[rx] These surface proteins are also highly expressed in several B-cell malignancies, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and diffuse large B-cell lymphoma (DLBCL).[rx]

Tafasitamab is a CD19-directed cytolytic monoclonal antibody that, upon binding and blocking the activity of CD19, causes lysis of B-cells. This process is mediated through both direct apoptosis and immune-mediated effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).[rx]

Tafasitamab induces a reduction in circulating B-cell counts by binding to a surface antigen, CD19, which is important for their survival.[rx] Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) experienced a 97% reduction in peripheral blood B-cell counts following 8 days of treatment, with a 100% reduction reached within 16 weeks of treatment.[rx]

Tafasitamab can cause infusion-related reactions, particularly during the initial cycles of therapy. Symptoms may include chills, flushing, dyspnea, and hypertension. Patients may be administered premedications (such as acetaminophen, antihistamines, or glucocorticoids) 0.5 – 2 hours prior to infusion to minimize infusion-related reactions.[rx] Tafasitamab may also cause significant myelosuppression, and subsequent infection, due to its mechanism of action – patients should undergo monitoring throughout therapy for signs of myelosuppression and/or infection.[rx]

Indications

  • Tafasitamab is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT).[rx]
  • Tafasitamab, in combination with lenalidomide, is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[rx]
  • Tafasitamab is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
  • This drug in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)
  • In the EU, injury is indicated in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.[rx]
  • Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Relapsed Diffuse large B-cell lymphoma NOS

Use in Cancer

Tafasitamab-cxix is approved to treat:

  • Diffuse large B-cell lymphoma (certain types) that has relapsed (come back) or is refractory (does not respond to treatment). It is used with lenalidomide in adults who cannot receive an autologous stem cell transplant.

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that tafasitamab-cxix provides a clinical benefit in these patients. Tafasitamab-cxix is also being studied in the treatment of other types of cancer.

Contraindications

  • a bad infection
  • anemia
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • pregnancy
  • a patient who is producing milk and breastfeeding

Dosage

Strengths: 200 mg

Lymphoma

12 mg/kg IV (based on actual body weight; Administer in combination with lenalidomide 25 mg orally for a maximum of 12 cycles, then continue this drug as monotherapy until disease progression or unacceptable toxicity:

  • CYCLE 1: 12 mg/kg IV on Days 1, 4, 8, 15, and 22
  • CYCLE 2: 12 mg/kg IV on Days 1, 8, 15, and 22
  • CYCLE 3: 12 mg/kg IV on Days 1 and 15
  • NOTE: Each therapy cycle is 28 days.
  • For the first infusion, use an infusion rate of 70 mL/h for the first 30 minutes, then increase the rate so that the infusion is administered within 1.5 to 2.5 hours; administer all subsequent infusions within 1.5 to 2 hours.
  • Refer to the lenalidomide prescribing information for lenalidomide dosage recommendations.
  • Administer premedications 30 minutes to 2 hours prior to starting infusion to minimize infusion-related reactions.
  • Premedications may include acetaminophen, histamine H1 receptor antagonists, histamine H2 receptor antagonists, and/or glucocorticosteroids.
  • For patients not experiencing infusion-related reactions during the first 3 infusions, premedication is optional for subsequent infusions.
  • If a patient experiences an infusion-related reaction, administer premedications before each subsequent infusion.

Dose Adjustments

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
INFUSION-RELATED REACTIONS (IRRS):

  • GRADE 2: Interrupt therapy and treat the IRR; when resolved to Grade 1, resume infusion at no more than 50% of the rate at which the reaction occurred; if the patient does not experience further reaction within 1 hour and vital signs are stable, the infusion rate may be increased every 30 minutes as tolerated to rate at which the reaction occurred.
  • GRADE 3: Interrupt therapy and treat the IRR; when resolved to Grade 1, resume infusion at no more than 25% of the rate at which the reaction occurred; if the patient does not experience further reaction within 1 hour and vital signs are stable, the infusion rate may be increased every 30 minutes as tolerated to a maximum of 50% of the rate at which the reaction occurred; if after rechallenge the reaction returns, stop the infusion immediately.
  • GRADE 4: Permanently discontinue therapy.

MYELOSUPPRESSION:

  • Platelet counts 50,000/mcL or less: Withhold this drug and lenalidomide and monitor complete blood count (CBC) weekly until the platelet count is 50,000/mcL or higher; resume this drug at the same dose and lenalidomide at a reduced dose (refer to lenalidomide prescribing information for dose modifications).
  • bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">Neutrophil count of 1000/mcL or less for at least 7 days OR neutrophil count of 1000/mcL or less with an increase of body temperature to 100.4F (38C) OR neutrophil count less than 500/mcL: Withhold this drug and lenalidomide and monitor CBC weekly until the neutrophil count is 1000/mcL or higher; ; resume this drug at the same dose and lenalidomide at a reduced dose (refer to lenalidomide prescribing information for dose modifications).

Administration advice:

  • Infuse the entire contents of the bag.
  • Do not coadminister other drugs through the same infusion line.
  • No incompatibilities have been observed between this drug with infusion containers made of polypropylene (PP), polyvinylchloride (PVC), polyethylene (PE), polyethylene terephthalate (PET), or glass and infusion sets made of polyurethane (PUR) or PVC.

Storage requirements:

  • Store unopened product refrigerated at 36F to 46F (2C to 8C) in the original carton to protect it from light. Do not shake. Do not freeze.
  • Use the reconstituted solution immediately.
  • If needed, store the reconstituted solution in the vial for a maximum of 12 hours either refrigerated at 36F to 46F (2C to 8C) or room temperature at 68F to 77F (20C to 25C) before dilution. Protect from light during storage.

Reconstitution/preparation techniques:

  • Reconstitute and dilute this drug prior to infusion.
  • The manufacturer’s product information should be consulted.

Side Effects

The Most Common

  • diarrhea
  • constipation
  • nausea
  • vomiting
  • loss of appetite
  • pain: Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।" data-rx-term="back pain" data-rx-definition="Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।">back pain
  • muscle spasms
  • sore throat, fever, chills, cough, burning or painful urination, or other signs of infection
  • fever or unusual bruising or bleeding
  • pale skin, fatigue, or shortness of breath

Drug Interactions

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on its mechanism of action, MONJUVI may cause fetal B-cell depletion when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on MONJUVI use in pregnant women to evaluate for a drug-associated risk. Animal reproductive toxicity studies have not been conducted with tafasitamab-cxix. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. MONJUVI is administered in combination with lenalidomide for up to 12 cycles. Lenalidomide can cause embryo-fetal harm and is contraindicated for use in pregnancy. Refer to the lenalidomide prescribing information for additional information. Lenalidomide is only available through a REMS
program.

Lactation

There are no data on the presence of tafasitamab-cxix in human milk or the effects on the breastfed child or milk production. Maternal immunoglobulin G is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to MONJUVI are unknown. Because of the potential for serious adverse reactions in the breastfed child, advise women not
to breastfeed during treatment with MONJUVI and for at least 3 months after the last dose. Refer to lenalidomide prescribing information for additional information.

Why is this medication prescribed?

Tafasitamab-cxix injection is used in adults along with lenalidomide (Revlimid) to treat certain types of non-Hodgkin’s lymphoma (types of cancer that begin in a type of white blood cells that normally fights infection) that have returned or that did not respond to other treatments in those who cannot receive a stem cell transplant. Tafasitamab-cxix injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells.

How should this medicine be used?

Tafasitamab-cxix comes as a powder to be mixed with a liquid and given into a vein by a doctor or nurse in a healthcare setting. Tafasitamab-cxix is usually given on days 1, 4, 8, 15, and 22 of cycle 1, on days 1, 8, 15 and 22 on cycles 2 and 3, and on days 1 and 15 of cycles 4 to 12. Each treatment cycle is 28 days and tafasitamab-cxix is given for up to 12 cycles. The length of treatment depends on how well your body responds to the medication and any side effects you experience.

Tafasitamab-cxix may cause serious reactions while you receive the medication. You may be given other medications to treat or help prevent reactions to tafasitamab-cxix. A doctor or nurse will watch you closely while you are receiving the infusion to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms: chills, flushing, headache, or shortness of breath.

Your doctor may temporarily or permanently stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with tafasitamab-cxix.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before receiving tafasitamab-cxix,

  • tell your doctor and pharmacist if you are allergic to tafasitamab-cxix, any other medications, or any of the ingredients in tafasitamab-cxix injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have an infection or if you have or have ever had an infection that keeps coming back.
  • tell your doctor if you are pregnant or plan to become pregnant. You should use birth control to prevent pregnancy during your treatment with tafasitamab-cxix and for at least 3 months after your final dose. Talk to your doctor about types of birth control that will work for you. If you become pregnant while receiving tafasitamab-cxix injection, call your doctor.
  • tell your doctor if you are breastfeeding. Do not breastfeed during your treatment with tafasitamab-cxix and for 3 months after your final dose.

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761163Orig1s000ltr.pdf
  4. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma
  5. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000OtherR.pdf
  6. https://pubchem.ncbi.nlm.nih.gov/compound/Tafasitamab-cxix
  7. https://pubchem.ncbi.nlm.nih.gov/substance/405226468
  8. https://www.cancer.gov/about-cancer/treatment/drugs/tafasitamab-cxix
  9. https://www.cancer.gov/about-cancer/treatment/drugs/tafasitamab-cxix
  10. https://go.drugbank.com/drugs/DB15044
  11. https://en.wikipedia.org/wiki/Tafasitamab
  12. https://www.webmd.com/drugs/2/drug-179868/tafasitamab-cxix-intravenous/details/list-contraindications
  13. https://www.drugs.com/pregnancy/tafasitamab.html
  14. https://medlineplus.gov/druginfo/meds/a620053.html
  15. https://pubchem.ncbi.nlm.nih.gov
  16. FDA Purple Book
    https://purplebooksearch.fda.gov/productdetails?query=761163
  17. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  18. NCI Cancer Drugs
    https://www.cancer.gov/policies/copyright-reuse
    https://www.cancer.gov/about-cancer/treatment/drugs/tafasitamab-cxix

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

Carbapenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Tafasitamab – Uses, Dosage, Side Effects, Interactions

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of action The CD19 surface antigen is a protein expressed on the surface of pre-B and mature B-lymphocytes[rx] that appears to play a role in enhancing B-cell receptor signaling and is considered integral to their survival.[rx] These surface proteins are also highly expressed in several B-cell malignancies, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and diffuse large B-cell lymphoma (DLBCL).[rx] Tafasitamab is a CD19-directed cytolytic monoclonal antibody that, upon binding and blocking the activity of CD19, causes lysis of B-cells. This process is mediated through both direct apoptosis and immune-mediated effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).[rx] Tafasitamab induces a reduction in circulating B-cell counts by binding to a surface antigen, CD19, which is important for their survival.[rx] Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) experienced a 97% reduction in peripheral blood B-cell counts following 8 days of treatment, with a 100% reduction reached within 16 weeks of treatment.[rx] Tafasitamab can cause infusion-related reactions, particularly during the initial cycles of therapy. Symptoms may include chills, flushing, dyspnea, and hypertension. Patients may be administered premedications (such as acetaminophen, antihistamines, or glucocorticoids) 0.5 - 2 hours prior to infusion to minimize infusion-related reactions.[rx] Tafasitamab may also cause significant myelosuppression, and subsequent infection, due to its mechanism of action - patients should undergo monitoring throughout therapy for signs of myelosuppression and/or infection.[rx] Indications Tafasitamab is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT).[rx] Tafasitamab, in combination with lenalidomide, is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[rx] Tafasitamab is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This drug in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT) In the EU, injury is indicated in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.[rx] Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Relapsed Diffuse large B-cell lymphoma NOS Use in Cancer Tafasitamab-cxix is approved to treat: Diffuse large B-cell lymphoma (certain types) that has relapsed (come back) or is refractory (does not respond to treatment). It is used with lenalidomide in adults who cannot receive an autologous stem cell transplant. This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that tafasitamab-cxix provides a clinical benefit in these patients. Tafasitamab-cxix is also being studied in the treatment of other types of cancer. Contraindications a bad infection anemia decreased blood platelets low levels of a type of white blood cell called neutrophils pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: 200 mg Lymphoma 12 mg/kg IV (based on actual body weight; Administer in combination with lenalidomide 25 mg orally for a maximum of 12 cycles, then continue this drug as monotherapy until disease progression or unacceptable toxicity: CYCLE 1: 12 mg/kg IV on Days 1, 4, 8, 15, and 22 CYCLE 2: 12 mg/kg IV on Days 1, 8, 15, and 22 CYCLE 3: 12 mg/kg IV on Days 1 and 15 NOTE: Each therapy cycle is 28 days. For the first infusion, use an infusion rate of 70 mL/h for the first 30 minutes, then increase the rate so that the infusion is administered within 1.5 to 2.5 hours; administer all subsequent infusions within 1.5 to 2 hours. Refer to the lenalidomide prescribing information for lenalidomide dosage recommendations. Administer premedications 30 minutes to 2 hours prior to starting infusion to minimize infusion-related reactions. Premedications may include acetaminophen, histamine H1 receptor antagonists, histamine H2 receptor antagonists, and/or glucocorticosteroids. For patients not experiencing infusion-related reactions during the first 3 infusions, premedication is optional for subsequent infusions. If a patient experiences an infusion-related reaction, administer premedications before each subsequent infusion. Dose Adjustments DOSE MODIFICATIONS FOR ADVERSE REACTIONS: INFUSION-RELATED REACTIONS (IRRS): GRADE 2: Interrupt therapy and treat the IRR; when resolved to Grade 1, resume infusion at no more than 50% of the rate at which the reaction occurred; if the patient does not experience further reaction within 1 hour and vital signs are stable, the infusion rate may be increased every 30 minutes as tolerated to rate at which the reaction occurred. GRADE 3: Interrupt therapy and treat the IRR; when resolved to Grade 1, resume infusion at no more than 25% of the rate at which the reaction occurred; if the patient does not experience further reaction within 1 hour and vital signs are stable, the infusion rate may be increased every 30 minutes as tolerated to a maximum of 50% of the rate at which the reaction occurred; if after rechallenge the reaction returns, stop the infusion immediately. GRADE 4: Permanently discontinue therapy. MYELOSUPPRESSION: Platelet counts 50,000/mcL or less: Withhold this drug and lenalidomide and monitor complete blood count (CBC) weekly until the platelet count is 50,000/mcL or higher; resume this drug at the same dose and lenalidomide at a reduced dose (refer to lenalidomide prescribing information for dose modifications). Neutrophil count of 1000/mcL or less for at least 7 days OR neutrophil count of 1000/mcL or less with an increase of body temperature to 100.4F (38C) OR neutrophil count less than 500/mcL: Withhold this drug and lenalidomide and monitor CBC weekly until the neutrophil count is 1000/mcL or higher; ; resume this drug at the same dose and lenalidomide at a reduced dose (refer to lenalidomide prescribing information for dose modifications). Administration advice: Infuse the entire contents of the bag. Do not coadminister other drugs through the same infusion line. No incompatibilities have been observed between this drug with infusion containers made of polypropylene (PP), polyvinylchloride (PVC), polyethylene (PE), polyethylene terephthalate (PET), or glass and infusion sets made of polyurethane (PUR) or PVC. Storage requirements: Store unopened product refrigerated at 36F to 46F (2C to 8C) in the original carton to protect it from light. Do not shake. Do not freeze. Use the reconstituted solution immediately. If needed, store the reconstituted solution in the vial for a maximum of 12 hours either refrigerated at 36F to 46F (2C to 8C) or room temperature at 68F to 77F (20C to 25C) before dilution. Protect from light during storage. Reconstitution/preparation techniques: Reconstitute and dilute this drug prior to infusion. The manufacturer's product information should be consulted. Side Effects The Most Common diarrhea constipation nausea vomiting loss of appetite back pain muscle spasms sore throat, fever, chills, cough, burning or painful urination, or other signs of infection fever or unusual bruising or bleeding pale skin, fatigue, or shortness of breath Drug Interactions DRUG INTERACTION Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Tafasitamab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Tafasitamab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Tafasitamab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tafasitamab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Tafasitamab. Ambroxol The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Ambroxol. Amivantamab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Tafasitamab. Ansuvimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Tafasitamab. Antilymphocyte immunoglobulin The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Tafasitamab. Antithymocyte immunoglobulin The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tafasitamab. Articaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Articaine. Asfotase alfa The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Tafasitamab. Atezolizumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Tafasitamab. Atoltivimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Atoltivimab. Avelumab The risk or severity of adverse effects can be increased when Avelumab is combined with Tafasitamab. Bamlanivimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Bamlanivimab. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Tafasitamab. Belantamab mafodotin The risk or severity of adverse effects can be increased when Tafasitamab is combined with Belantamab mafodotin. Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Tafasitamab. Benralizumab The risk or severity of adverse effects can be increased when Benralizumab is combined with Tafasitamab. Benzocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Benzyl alcohol. Besilesomab The risk or severity of adverse effects can be increased when Besilesomab is combined with Tafasitamab. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tafasitamab. Bezlotoxumab The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Tafasitamab. Bimekizumab The risk or severity of adverse effects can be increased when Bimekizumab is combined with Tafasitamab. Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tafasitamab. Brentuximab vedotin The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tafasitamab. Brodalumab The risk or severity of adverse effects can be increased when Brodalumab is combined with Tafasitamab. Brolucizumab The risk or severity of adverse effects can be increased when Brolucizumab is combined with Tafasitamab. Bupivacaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Bupivacaine. Burosumab The risk or severity of adverse effects can be increased when Burosumab is combined with Tafasitamab. Butacaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Butamben. Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Tafasitamab. Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tafasitamab. Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tafasitamab. Capsaicin The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Capsaicin. Casirivimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Catumaxomab is combined with Tafasitamab. Cemiplimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Tafasitamab. Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Tafasitamab. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tafasitamab. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Chloroprocaine. Cilgavimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Cilgavimab. Cinchocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Cinchocaine. Cocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Cocaine. Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Tafasitamab. Daratumumab The risk or severity of adverse effects can be increased when Daratumumab is combined with Tafasitamab. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tafasitamab. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Tafasitamab. Dienestrol Dienestrol may increase the thrombogenic activities of Tafasitamab. Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Tafasitamab. Digoxin Immune Fab The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tafasitamab. Dinutuximab The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tafasitamab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Diphenhydramine. Dostarlimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Dostarlimab. Dulaglutide The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tafasitamab. Dupilumab The risk or severity of adverse effects can be increased when Dupilumab is combined with Tafasitamab. Durvalumab The risk or severity of adverse effects can be increased when Durvalumab is combined with Tafasitamab. Dyclonine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Dyclonine. Ebola Zaire vaccine (live The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Tafasitamab. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Tafasitamab. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Tafasitamab. Eflapegrastim The risk or severity of adverse effects can be increased when Eflapegrastim is combined with Tafasitamab. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Tafasitamab. Elotuzumab The risk or severity of adverse effects can be increased when Elotuzumab is combined with Tafasitamab. Emapalumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Tafasitamab. Emicizumab The risk or severity of adverse effects can be increased when Emicizumab is combined with Tafasitamab. Eptinezumab The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tafasitamab. Erenumab The risk or severity of adverse effects can be increased when Erenumab is combined with Tafasitamab. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tafasitamab. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Tafasitamab. Estetrol Estetrol may increase the thrombogenic activities of Tafasitamab. Estradiol Estradiol may increase the thrombogenic activities of Tafasitamab. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Tafasitamab. Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Tafasitamab. Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Tafasitamab. Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Tafasitamab. Estriol Estriol may increase the thrombogenic activities of Tafasitamab. Estrone Estrone may increase the thrombogenic activities of Tafasitamab. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Tafasitamab. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Tafasitamab. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Etidocaine. Evolocumab The risk or severity of adverse effects can be increased when Evolocumab is combined with Tafasitamab. Fanolesomab The risk or severity of adverse effects can be increased when Fanolesomab is combined with Tafasitamab. Fremanezumab The risk or severity of adverse effects can be increased when Fremanezumab is combined with Tafasitamab. Galcanezumab The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tafasitamab. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tafasitamab. Glofitamab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Glofitamab. Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Tafasitamab. Guselkumab The risk or severity of adverse effects can be increased when Guselkumab is combined with Tafasitamab. Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tafasitamab. Human cytomegalovirus globulin The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Tafasitamab. Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tafasitamab. Human Rho(D) immune globulin The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Tafasitamab. Human varicella-zoster i The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Tafasitamab. Ibalizumab The risk or severity of adverse effects can be increased when Ibalizumab is combined with Tafasitamab. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tafasitamab. Idarucizumab The risk or severity of adverse effects can be increased when Idarucizumab is combined with Tafasitamab. Imdevimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Imdevimab. Imlifidase The therapeutic efficacy of Tafasitamab can be decreased when used in combination with Imlifidase. Inebilizumab The risk or severity of adverse effects can be increased when Inebilizumab is combined with Tafasitamab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Tafasitamab. Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tafasitamab. Ipilimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tafasitamab. Isatuximab The risk or severity of adverse effects can be increased when Isatuximab is combined with Tafasitamab. Ixekizumab The risk or severity of adverse effects can be increased when Ixekizumab is combined with Tafasitamab. Lanadelumab The risk or severity of adverse effects can be increased when Lanadelumab is combined with Tafasitamab. Lecanemab The risk or severity of adverse effects can be increased when Lecanemab is combined with Tafasitamab. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Levobupivacaine. Lidocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Lidocaine. Loncastuximab tesirine The risk or severity of adverse effects can be increased when Tafasitamab is combined with Loncastuximab tesirine. Maftivimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Maftivimab. Margetuximab The risk or severity of adverse effects can be increased when Margetuximab is combined with Tafasitamab. Meloxicam The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Tafasitamab. Mestranol Mestranol may increase the thrombogenic activities of Tafasitamab. Methoxy polyethylen The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tafasitamab. Mirvetuximab soravtansine The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Tafasitamab. Mogamulizumab The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tafasitamab. Mosunetuzumab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Mosunetuzumab. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Tafasitamab. Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Tafasitamab. Necitumumab The risk or severity of adverse effects can be increased when Necitumumab is combined with Tafasitamab. Nivolumab The risk or severity of adverse effects can be increased when Nivolumab is combined with Tafasitamab. Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tafasitamab. Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tafasitamab. Ocrelizumab The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Tafasitamab. Odesivimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tafasitamab. Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Tafasitamab. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tafasitamab. Oxetacaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Oxybuprocaine. Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Tafasitamab. Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Tafasitamab. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tafasitamab. Pembrolizumab The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Tafasitamab. Pertuzumab The risk or severity of adverse effects can be increased when Pertuzumab is combined with Tafasitamab. Phenol The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Phenol. Polatuzumab vedotin The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tafasitamab. Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Tafasitamab. Pramocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Pramocaine. Prilocaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Procaine. Proparacaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Propoxycaine. Quinestrol Quinestrol may increase the thrombogenic activities of Tafasitamab. Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tafasitamab. Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tafasitamab. Ravulizumab The risk or severity of adverse effects can be increased when Ravulizumab is combined with Tafasitamab. Raxibacumab The risk or severity of adverse effects can be increased when Raxibacumab is combined with Tafasitamab. Relatlimab The risk or severity of adverse effects can be increased when Relatlimab is combined with Tafasitamab. Reslizumab The risk or severity of adverse effects can be increased when Reslizumab is combined with Tafasitamab. Risankizumab The risk or severity of adverse effects can be increased when Risankizumab is combined with Tafasitamab. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Tafasitamab. Romosozumab The risk or severity of adverse effects can be increased when Romosozumab is combined with Tafasitamab. Ropivacaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Ropivacaine. Sacituzumab govitecan The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tafasitamab. Sarilumab The risk or severity of adverse effects can be increased when Sarilumab is combined with Tafasitamab. Secukinumab The risk or severity of adverse effects can be increased when Secukinumab is combined with Tafasitamab. Siltuximab The risk or severity of adverse effects can be increased when Siltuximab is combined with Tafasitamab. Sotrovimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Spesolimab. Sulesomab The risk or severity of adverse effects can be increased when Sulesomab is combined with Tafasitamab. Sutimlimab The risk or severity of adverse effects can be increased when Sutimlimab is combined with Tafasitamab. S Conj Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tafasitamab. S Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tafasitamab. Teplizumab The risk or severity of adverse effects can be increased when Teplizumab is combined with Tafasitamab. Tetanus immu globulin The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Tafasitamab. Tetracaine The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Tetracaine. Tezepelumab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Tezepelumab. Tibolone Tibolone may increase the thrombogenic activities of Tafasitamab. Tildrakizumab The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Tafasitamab. Tisotumab vedotin The risk or severity of adverse effects can be increased when Tafasitamab is combined with Tisotumab vedotin. Tixagevimab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Tixagevimab. Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Tafasitamab. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Tafasitamab. Tralokinumab The risk or severity of adverse effects can be increased when Tralokinumab is combined with Tafasitamab. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tafasitamab. Trastuzumab deruxtecan The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Tafasitamab. Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tafasitamab. Tremelimumab The risk or severity of adverse effects can be increased when Tremelimumab is combined with Tafasitamab. Ublituximab The risk or severity of adverse effects can be increased when Ublituximab is combined with Tafasitamab. Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tafasitamab. Vedolizumab The risk or severity of adverse effects can be increased when Vedolizumab is combined with Tafasitamab. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on its mechanism of action, MONJUVI may cause fetal B-cell depletion when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on MONJUVI use in pregnant women to evaluate for a drug-associated risk. Animal reproductive toxicity studies have not been conducted with tafasitamab-cxix. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. MONJUVI is administered in combination with lenalidomide for up to 12 cycles. Lenalidomide can cause embryo-fetal harm and is contraindicated for use in pregnancy. Refer to the lenalidomide prescribing information for additional information. Lenalidomide is only available through a REMS program. Lactation There are no data on the presence of tafasitamab-cxix in human milk or the effects on the breastfed child or milk production. Maternal immunoglobulin G is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to MONJUVI are unknown. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with MONJUVI and for at least 3 months after the last dose. Refer to lenalidomide prescribing information for additional information. Why is this medication prescribed?

Tafasitamab-cxix injection is used in adults along with lenalidomide (Revlimid) to treat certain types of non-Hodgkin's lymphoma (types of cancer that begin in a type of white blood cells that normally fights infection) that have returned or that did not respond to other treatments in those who cannot receive a stem cell transplant. Tafasitamab-cxix injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells.

How should this medicine be used?

Tafasitamab-cxix comes as a powder to be mixed with a liquid and given into a vein by a doctor or nurse in a healthcare setting. Tafasitamab-cxix is usually given on days 1, 4, 8, 15, and 22 of cycle 1, on days 1, 8, 15 and 22 on cycles 2 and 3, and on days 1 and 15 of cycles 4 to 12. Each treatment cycle is 28 days and tafasitamab-cxix is given for up to 12 cycles. The length…

A global war against illness

Help this medical guide reach someone who may need it

Share reliable health information with a patient, family member, caregiver, or colleague. Reading and awareness can help people ask better questions and seek appropriate care.

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)